Related Articles
Q.12. Buprenorphine
Ā Q.12: Buprenorphine Sublingual Tablets are indicated for the treatment of opioid dependence. Which of the following statement is correct regarding Buprenorphine?Ā (a) Induction with buprenorphine…
Esketamine (Spravato) FDA approved for Treatment Resistant Depression.
Esketamine is a glutamate receptor modulator: acts as noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. On March 05, 2019: FDA approved Spravato (esketamine) nasal spray, as an…
Cariprazine (Vraylar) Approved for Depressive Episodes in Bipolar I Disorder
Cariprazine (Vraylar) was initially approved for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This week FDA also approved…
Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
Journal Club #3: Bipolar Depression Guidelines: CANMAT & ISBD Versus Psychopharmacology Algorithm Project
Today we posted the following third journal club in PEFA Journal Club’s discussion series: Journal Club #3: The Psychopharmacology Algorithm Project at the Harvard South…